apaziquone and Cell-Transformation--Neoplastic

apaziquone has been researched along with Cell-Transformation--Neoplastic* in 1 studies

Other Studies

1 other study(ies) available for apaziquone and Cell-Transformation--Neoplastic

ArticleYear
Oncogenic potential of bifunctional bioreductive drugs.
    The British journal of cancer. Supplement, 1996, Volume: 27

    Potential oncogenicity must be a factor of concern in the design and development of novel bioreductive drugs. In the present studies, the cytotoxicity and oncogenic transforming potential of a series of heterocyclic mono-N-oxides, designed to be used as bioreductive drugs, were examined using the mouse C3H 10T1/2 cell system. Exponential phase cultures of 10T1/2 cells were treated with graded doses of the bioreductive drugs for a 4 h period, either in air or hypoxia, at 37 degrees C. After treatment, cultures were replated for both survival and transformation assays. The fused pyrazine mono-N-oxide RB 90740 and its N-deoxy analogue, RB 92816, demonstrated a dose-dependent cytotoxicity and oncogenic transforming potency under aerobic conditions. Similarly, the indoloquinone E09 and the structurally related mitomycin C demonstrated dose dependence in both toxicity and oncogenic transforming potential. The most cytotoxic aromatic-N-oxides tested, RB 92816, also demonstrated the highest oncogenic transformation incidence. In hypoxia, the bioreductive metabolites of RB 90740 were substantially more cytotoxic and induced a higher oncogenic transformation yield than the drug in air. These data are consistent with the structure-activity relationship for bioreductive drugs in that heterocyclic-N-oxides with reactive side chains such as RB 92816 are cytotoxic and potentially carcinogenic.

    Topics: Animals; Antineoplastic Agents; Aziridines; Cell Survival; Cell Transformation, Neoplastic; Indolequinones; Indoles; Mice; Mice, Inbred C3H; Mitomycin; Oxidation-Reduction; Pyrazines; Structure-Activity Relationship

1996